ALLIANCES (Gilead) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Alliances Statement [Line Items]
Net product sales									$ 12,304	$ 13,654	$ 17,622
Alliance and other revenues									4,081	3,967	3,622
Total Revenues	4,441	4,065	4,048	3,831	4,191	3,736	4,443	5,251	16,385	17,621	21,244
Equity in net loss of affiliates									(166)	(183)	(281)
Deferred income	1,525				4,849				1,525	4,849
Gilead [Member] | Bulk efavirenz component of Atripla [Member]
Alliances Statement [Line Items]
Total number of months to receive royalty payments from alliance	36 months								36 months
Percentage of net sales recognized first year following the termination	55.00%								55.00%
Percentage of net sales recognized second year following the termination	35.00%								35.00%
Percentage of net sales recognized third year following the termination of the agreement	15.00%								15.00%
Net product sales											1
Alliance and other revenues									1,366	1,267	1,203
Total Revenues									1,366	1,267	1,204
Equity in net loss of affiliates									17	18	16
Deferred income	$ 468				$ 339				$ 468	$ 339